Ligand Pharmaceuticals
Builds biopharmaceutical royalty portfolios and licenses Captisol and NITRICIL drug technologies.
$280.49
After-hours close−0.11 (−0.04%)
At close$280.60(−1.38%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 148.51%Insiders 2.46%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 20.04M · Float 19.55M · 97.5% free float
Institutions13F, as of Jun 30, 2026
427 holders · 29.76M shares · 99 new positions · 247 increased · 117 reduced · 40 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.10M | 15.47% | +139.1K | Aug 7, 2026 |
| Invesco Ltd. | 1.20M | 6.00% | +378.0K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 1.14M | 5.68% | +38.0K | Aug 13, 2026 |
| Jupiter Topco LLC | 1.04M | 5.19% | +1.04Mnew | Aug 14, 2026 |
| Vanguard Capital Management LLC | 871.0K | 4.35% | +22.9K | Aug 13, 2026 |
| State Street Corp | 826.5K | 4.12% | +47.7K | Aug 7, 2026 |
| FMR LLC | 762.8K | 3.81% | +166.7K | Aug 13, 2026 |
| Franklin Resources Inc | 752.0K | 3.75% | +178.9K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.50% | 2.84M | 13G | Oct 17, 2025 ↗ |
| Invesco Ltd. | 6.10% | 1.22M | 13G | Aug 13, 2026 ↗ |
| Vanguard Portfolio Management | 5.56% | 1.11M | 13G | May 1, 2026 ↗ |
| Janus Henderson Group PLC | 5.30% | 1.04M | 13G | Nov 14, 2025 ↗ |
| Vanguard Capital Management | 5.00% | 997.6K | 13G | May 1, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Todd C. Davis | director, officer: Chief Executive Officer | 199.5K | 1.00% | Jul 6, 2026 |
| Jason Aryeh | director | 102.6K | 0.51% | Jun 12, 2026 |
| John W. Kozarich | director | 42.6K | 0.21% | Jun 9, 2026 |
| Andrew Reardon | officer: CLO & Secretary | 41.5K | 0.21% | Aug 4, 2026 |
| Stephen L. Sabba | director | 33.6K | 0.17% | Jun 18, 2026 |
| Octavio Espinoza | officer: Chief Financial Officer | 27.7K | 0.14% | Aug 14, 2026 |
| John L. Lamattina | director | 27.0K | 0.13% | Jun 12, 2026 |
| Nancy Ryan Gray | director | 8.9K | 0.04% | Jun 9, 2026 |
| Martine Zimmermann | director | 5.1K | 0.03% | Jun 9, 2026 |
| Jason Haas | director | 4.0K | 0.02% | Aug 14, 2026 |
35 people have not refiled in the last 18 months (2.29M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 12, 2026 | Jason Haasdirector | Sale | 7,138 | $292.81 | 3,981 |
| Aug 12, 2026 | Octavio Espinozaofficer: Chief Financial Officer | Sale | 31,641 | $292.07 | 27,696 |
| Aug 3, 2026 | Andrew Reardonofficer: CLO & Secretary | Sale · 10 lots | 5,000 | $288.99 | 41,514 |
| Jul 1, 2026 | Andrew Reardonofficer: CLO & Secretary | Sale · 8 lots | 5,000 | $313.28 | 41,514 |
| Jun 16, 2026 | Stephen L. Sabbadirector | Sale | 2,145 | $254.00 | 33,629 |
| Jun 12, 2026 | Jason Haasdirector | Sale · 2 lots | 6,461 | $255.58 | 4,981 |
| Jun 10, 2026 | John L. Lamattinadirector | Sale · 4 lots | 4,591 | $250.88 | 26,969 |
| Jun 11, 2026 | Jason Aryehdirector | Sale | 4,500 | $250.00 | 102,580 |
| Jun 10, 2026 | Jason Aryehdirector | Sale | 500 | $250.00 | 107,080 |
| Jun 1, 2026 | Andrew Reardonofficer: CLO & Secretary | Sale · 7 lots | 5,000 | $227.06 | 41,382 |
CongressHouse and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Gilbert Cisneros · CA31 | Purchase | $1,001 – $15,000 | May 29, 2026 | Jun 9, 2026 ↗ |